Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Current Leases (2023 - 2025)

Historic Current Leases for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $1.5 million.

  • Contineum Therapeutics' Current Leases rose 14173.49% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 14173.49%. This contributed to the annual value of $1.5 million for FY2024, which is 21293.1% up from last year.
  • Contineum Therapeutics' Current Leases amounted to $1.5 million in Q3 2025, which was up 14173.49% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Current Leases registered a high of $1.5 million during Q3 2025, and its lowest value of $464000.0 during Q4 2023.
  • For the 3-year period, Contineum Therapeutics' Current Leases averaged around $985375.0, with its median value being $1.0 million (2024).
  • Its Current Leases has fluctuated over the past 5 years, first surged by 21293.1% in 2024, then soared by 14173.49% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Current Leases stood at $464000.0 in 2023, then surged by 212.93% to $1.5 million in 2024, then grew by 1.72% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.5 million for Q2 2025, and $1.5 million during Q1 2025.